

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
Next List	Bottom	View Cart		

Searching 1976 to present...

Results of Search in 1976 to present db for:
(AN/Schering AND contraceptive): 74 patents.

Hits 1 through 50 out of 74

09/09/01, 665

Next 50 Hits

Jump To

Refine Search

an/(Schering) and contraceptive and gestagen

PAT. NO.	Title
1 6,841,548	T Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives
2 6,825,329	T Human PEM as a target for birth control and treatment of Alzheimer's disease
3 6,794,409	T Use of ER.beta.-selective ligands for regulating fertility and compounds useful therefor
4 6,790,853	T Contraception method using competitive progesterone antagonists and novel compounds useful therein
5 6,787,531	T Pharmaceutical composition for use as a contraceptive
6 6,670,347	T 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring
7 6,653,298	T Composition
8 RE38,253	T Composition for contraception
9 6,610,670	T Cyclodextrin-drospirenone inclusion complexes
10 6,608,074	T Contraception method using competitive progesterone antagonists and novel compounds useful therein
11 6,596,713	T Steroid esters and amides, process for their production and their pharmaceutical use
12 6,548,534	T Nonsteroidal gestagens
13 6,451,780	T Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
14 RE37,838	T Composition for contraception
15 6,407,086	T Meiosis regulating compounds
16 6,362,237	T Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
17 RE37,564	T Composition for contraception

- 18 [6,344,454](#) **T** [Nonsteroidal gestagens](#)
 - 19 [6,344,442](#) **T** [Zona pellucida proteins for contraception](#)
 - 20 [6,340,688](#) **T** [Contraception method using competitive progesterone antagonists and novel compounds useful therein](#)
 - 21 [6,312,722](#) **T** [Pharmaceutical combined preparation, kit and method for hormonal contraception](#)
 - 22 [6,245,804](#) **T** [Nonsteroidal gestagens](#)
 - 23 [6,225,297](#) **T** [Combination contraceptive](#)
 - 24 [6,177,416](#) **T** [Oxyiminopregnancarb lactones](#)
 - 25 [6,147,065](#) **T** [14- \$\alpha\$, 17- \$\alpha\$ -C.sub.2 bridged norprogesterone derivatives](#)
 - 26 [6,143,754](#) **T** [Competitive progesterone antagonist for demand-oriented female birth control](#)
 - 27 [6,043,234](#) **T** [Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen](#)
 - 28 [6,027,749](#) **T** [Pharmaceutical combined preparation, kit and method for hormonal contraception](#)
 - 29 [5,980,940](#) **T** [Pharmaceutical combination preparation for hormonal contraception](#)
 - 30 [5,973,172](#) **T** [14- \$\alpha\$, 17- \$\alpha\$ -C.sub.2 -bridged norprogesterone derivatives](#)
 - 31 [5,958,878](#) **T** [Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors](#)
 - 32 [5,858,394](#) **T** [Agent for transdermal administration that contains gestodene esters](#)
 - 33 [5,827,842](#) **T** [14- \$\alpha\$, 17- \$\alpha\$ -C.sub.2 -bridged norprogesterone derivatives](#)
 - 34 [5,824,667](#) **T** [Composition for contraception](#)
 - 35 [5,756,490](#) **T** [Pharmaceutical combination preparation for hormonal contraception](#)
 - 36 [5,719,136](#) **T** [Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women](#)
 - 37 [5,601,814](#) **T** [Use of IL-6 to treat toxic shock](#)
 - 38 [5,595,970](#) **T** [Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors](#)
 - 39 [5,569,652](#) **T** [Dihydrospirorenone as an antiandrogen](#)
 - 40 [5,531,703](#) **T** [Applicator for semisolid medications](#)
 - 41 [5,529,993](#) **T** [14- \$\alpha\$, 17- \$\alpha\$ -ethano-16- \$\alpha\$ -hydroxy-estratrienes](#)
 - 42 [5,439,913](#) **T** [Contraception method using competitive progesterone antagonists and novel compounds useful therein](#)
 - 43 [4,977,147](#) **T** [17-methylene- and 17-ethylidene-estratrienes](#)
 - 44 [4,891,365](#) **T** [17-Substituted estradienes and estratrienes](#)
 - 45 [4,794,119](#) **T** [Aqueous crystalline suspension of steroid glycoesters](#)
 - 46 [4,780,460](#) **T** [Glycoesters of estradiol and estriol](#)
 - 47 [4,719,054](#) **T** [Process for the production of 17- \$\alpha\$ -ethynyl-17- \$\beta\$ -hydroxy-18-methyl-4,15-estradien-3-one, and novel 3,5-estradien-17-one starting compounds for this process](#)
 - 48 [4,681,875](#) **T** [3,17- \$\beta\$ -estriol diesters, methods of their use, and pharmaceutical preparations containing them](#)
 - 49 [4,670,427](#) **T** [1- \$\alpha\$, 2- \$\alpha\$ -methylene-6-methylene- and 6- \$\alpha\$ -methylpregnenes, their preparation and pharmaceutical use](#)
 - 50 [4,621,079](#) **T** [Multistage combination preparation and its use for oral contraception](#)
-